MIRM
$88.51-2.21 (-2.44%)
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and ...
Recent News
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.
Mirum Pharmaceuticals (MIRM) Completes Enrollment for Phase 3 EXPAND Study of LIVMARLI
Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the most promising stocks under $100 to buy. On March 16, Mirum Pharmaceuticals announced the completion of enrollment for its Phase 3 EXPAND study, which evaluates the efficacy and safety of LIVMARLI (maralixibat) in treating cholestatic pruritus. This randomized, double-blind, placebo-controlled trial focuses on patients aged 6 months […]
Mirum EXPAND Enrollment Milestone Highlights LIVMARLI Upside And Valuation Gap
Mirum Pharmaceuticals (NasdaqGM:MIRM) has completed enrollment in the Phase 3 EXPAND study of LIVMARLI. The EXPAND trial is designed to support a potential label expansion for treating cholestatic pruritus across a broader range of rare cholestatic liver diseases, including biliary atresia. This represents a key corporate milestone as the company progresses a pivotal program aimed at addressing a wider patient population with unmet needs. Mirum Pharmaceuticals focuses on therapies for rare...
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli
MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases. Top-line data due in Q4 2026.